Table 1.
Participant characteristics in a cohort of 190 colorectal cancer patients based on F. nucleatum DNA status in colorectal cancer tissue
| Low tumor F. nucleatum1 | High tumor F. nucleatum2 | P value | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Total | 129 | (68.2) | 61 | (31.8) | |
| Age at surgery | |||||
| Under 60 | 22 | (17.1) | 9 | (14.8) | 0.95 |
| 60–< 70 | 51 | (39.5) | 23 | (37.7) | |
| 70–< 80 | 36 | (27.9) | 19 | (31.1) | |
| 80+ | 20 | (15.5) | 10 | (16.4) | |
| Sex | |||||
| Female | 40 | (31) | 20 | (32.8) | 0.81 |
| Male | 89 | (69) | 41 | (67.2) | |
| Tumor stage | |||||
| I | 25 | (19.4) | 9 | (14.8) | 0.238 |
| II | 36 | (27.9) | 23 | (37.7) | |
| III | 44 | (34.1) | 14 | (23) | |
| IV | 22 | (17.1) | 14 | (23) | |
| Unknown | 2 | (1.6) | 1 | (1.6) | |
| Tumor location | |||||
| Proximal colon | 39 | (30.2) | 22 | (36.1) | 0.58 |
| Distal colon | 38 | (29.5) | 14 | (23) | |
| Rectal | 52 | (40.3) | 25 | (41) | |
| Neo/adjuvant treatment3 | |||||
| No | 89 | (69) | 34 | (55.7) | 0.07 |
| Yes | 40 | (31) | 27 | (44.3) | |
| Smoking history | |||||
| Never | 48 | (43.6) | 24 | (45.3) | 0.84 |
| Ever | 62 | (56.4) | 29 | (54.7) | |
| Missing | 19 | (14.5) | 8 | (13.1) | |
| Body Mass Index | |||||
| 18.5–< 25 | 49 | (38) | 18 | (29.5) | 0.61 |
| 25–< 30 | 39 | (30.2) | 21 | (34.4) | |
| 30+ | 16 | (12.4) | 7 | (11.5) | |
| Missing | 25 | (19.4) | 15 | (24.6) | |
| F. nucleatum DNA in non-malignant, adjacent tissue | |||||
| Low1 | 117 | (90.7) | 36 | (59.0) | |
| High2 | 10 | (7.8) | 24 | (39.3) | < 0.001 |
| Missing | 2 | (1.6) | 1 | (1.6) | |
| Microsatellite instability status | |||||
| MSS/MSI-L | 105 | (81.4) | 40 | (65.6) | |
| MSI-H | 3 | (2.3) | 10 | (16.4) | < 0.001 |
| Missing | 21 | (16.3) | 11 | (18.0) | |
| KRAS status | |||||
| Wild type | 57 | (44.2) | 18 | (29.5) | |
| Mutated | 30 | (23.3) | 17 | (27.9) | 0.15 |
| Missing | 42 | (32.6) | 26 | (42.6) | |
| NRAS status | |||||
| Wild type | 80 | (62.0) | 34 | (55.7) | |
| Mutated | 7 | (5.4) | 1 | (1.6) | 0.30 |
| Missing | 42 | (32.6) | 26 | (42.6) | |
| BRAF status | |||||
| Wild type | 81 | (62.8) | 31 | (50.8) | |
| Mutated | 6 | (4.7) | 4 | (6.6) | 0.41 |
| Missing | 42 | (32.6) | 26 | (42.6) | |
| PIK3CA status | |||||
| Wild type | 78 | (60.5) | 31 | (50.8) | |
| Mutated | 9 | (7.0) | 4 | (6.6) | 0.86 |
| Missing | 42 | (32.6) | 26 | (42.6) | |
1No F. nucleatum DNA detected within 42 PCR cycles or F. nucleatum (2−∆CT) below 0.0008 (i.e., the median among individuals with tumor F. nucleatum DNA detected in 42 PCR cycles)
2F. nucleatum (2−∆CT) above 0.0008
3Neo-adjuvant or adjuvant radiotherapy or chemotherapy within 6 months of surgery